WO2011126163A1 - Composition de blanchiment de la peau contenant un dipeptide - Google Patents

Composition de blanchiment de la peau contenant un dipeptide Download PDF

Info

Publication number
WO2011126163A1
WO2011126163A1 PCT/KR2010/002159 KR2010002159W WO2011126163A1 WO 2011126163 A1 WO2011126163 A1 WO 2011126163A1 KR 2010002159 W KR2010002159 W KR 2010002159W WO 2011126163 A1 WO2011126163 A1 WO 2011126163A1
Authority
WO
WIPO (PCT)
Prior art keywords
arginine
cysteine
tryptophan
tyrosine
valine
Prior art date
Application number
PCT/KR2010/002159
Other languages
English (en)
Korean (ko)
Inventor
박소희
이현경
최혜령
Original Assignee
주식회사 웰스킨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 웰스킨 filed Critical 주식회사 웰스킨
Priority to PCT/KR2010/002159 priority Critical patent/WO2011126163A1/fr
Publication of WO2011126163A1 publication Critical patent/WO2011126163A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof

Definitions

  • the present invention relates to a composition for skin whitening comprising a peptide, and more particularly to a composition for skin whitening comprising a peptide consisting of two amino acids.
  • the pigments that determine human skin color include melanin, hemoglobin, and carotenoids, and various pigments of human skin, hair, and eyes appear by these pigments.
  • Melanin is the conversion of tyrosine, an amino acid from melanocytes, to dopa-quinone by tyrosinase. Beginning, a series of oxidation processes are followed to form a brown (pheomelanin) or black (eumelanin) polymer.
  • the melanin production process is a reaction involving an enzyme in a rate control step called tyrosinase, and it can be expected to whiten the skin by inhibiting the activity of tyrosinase.
  • Korean Patent Application No. 10-2002-0016298 (Melanin Production Inhibition Peptides, Method of Preparation, and External Skin Composition Containing the Same), as a peptide consisting of four amino acids, in particular It has been reported that the first amino acid and the second amino acid are selected from tyrosine or tryptophan, and the third amino acid has a whitening effect on a peptide consisting of four amino acids consisting of tryptophan and fourth amino acid.
  • Republic of Korea Patent No. 10-0760875 is a cosmetic composition containing a gelatin peptide derived from fish for skin whitening such as blemishes, freckles, etc. by inhibiting the production of melanin in the cells .
  • the peptide compound has an amino acid sequence of glycine-proline-hydroxyproline (Glycine-Proline-Hydroxyproline) in the molecule, has been reported skin whitening cosmetic composition, characterized in that consisting of 3 to 20 amino acids.
  • an object of the present invention is to determine whether a skin whitening ability is present in a short peptide, that is, a peptide consisting of two amino acids, and to develop and provide a composition for skin whitening including a peptide whose efficacy has been confirmed.
  • the present invention provides a composition for skin whitening comprising at least one dipeptide consisting of two amino acids belonging to any one group selected from the following groups A to C.
  • the composition for skin whitening of the present invention preferably contains 0.001 to 30% by weight of any one or more dipeptides selected from the groups A to C, when the content is less than 0.001% by weight, the whitening effect is insignificant If the amount exceeds 30% by weight, the effect of increasing the amount of addition is minimal.
  • the product form and formulation of the composition can be applied to the outside of the skin, including the form of a pack, cosmetics (or cosmetics) or drugs, and paste, liquid Or all other formulations, including powders, if they are suspended in liquid form and can be used on the skin.
  • cosmetics include skins, lotions, creams, foundations, essences, gels, packs, foam cleansing, soaps, and the like.
  • an appropriate amount may be additionally selected and optionally selected from oils, water, surfactants, humectants, lower alcohols, thickeners, chelating agents, pigments, preservatives, fragrances, and the like.
  • the composition of the present invention may add a sunscreen, a light scattering agent and the like.
  • composition for skin whitening comprising the dipeptide of the present invention may be a pharmaceutical composition for parenteral (subcutaneous) administration, and may include a pharmaceutically acceptable carrier according to the formulation and the method of use.
  • the pharmaceutical composition is preferably used once or three times at 10 to 50 mg per day, and the number of doses and dosages may be adjusted according to a medical condition or by a doctor's prescription.
  • the present invention provides a composition for whitening comprising a dipeptide belonging to groups A to C, the whitening efficacy is greatly increased compared to the known tetrapeptide (tetrapeptide), and by using a small peptide can greatly reduce the cost It works.
  • Peptides belonging to Groups A to C of the present invention with whitening ability can be used as dermatological medicines such as cosmetic (cosmetic) compositions or ointments by use alone or in combination with other skin whitening ingredients.
  • the present inventors selected and linked two of 20 amino acids to prepare 400 dipeptides, and then examined the presence of whitening ability.
  • in vitro tyrosinase enzyme inhibition method to determine the whitening effect on the cells to find a whitening material that can actually work.
  • Cells used to confirm the whitening efficacy in the present invention is a B16 malignant melanoma cell line and an immortalized mouse melanocyte cell line Mel-Ab cell.
  • B16 malignant melanoma cell line is the most frequently used melanoma cell line to detect whitening efficacy. In the process of whitening efficacy, alpha-MSH is used to increase melanin production and then its inhibitory effect is measured. A) It is a good cell line that can search for whitening materials that act by inhibiting mechanisms. (Choi MY, Song HS, Hur HS, Sim SS.Whitening activity of luteolin related to the inhibition of cAMP pathway in alpha-MSH-stimulated B16 melanoma cells.Arch Pharm Res. 2008 Sep; 31 (9): 1166-71. Epub 2008 Sep 20)
  • Mel-Ab cells which are immortalized cell lines of mice, are cultured by adding TPA at the time of cell culture, which is a good cell line to search for whitening materials that act by inhibiting PKC (Protein Kinase C) mechanism.
  • PKC Protein Kinase C
  • Park HY Russakovsky V, Ao Y, Fernandez E, Gilchrest BA.Alpha-melanocyte stimulating hormone-induced pigmentation is blocked by depletion of protein kinase C, Exp Cell Res. 1996 Aug 25; 227 (1): 70-9) / Park HY, Lee J, GonzS, Middelkamp-Hup MA, Kapasi S, Peterson S, Gilchrest BA. Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation. J Invest Dermatol. 2004 Jan; 122 (1): 159-66).
  • the present invention was to search for whitening materials based on various mechanisms of action by searching for whitening efficacy using cell lines having two different characteristics.
  • B16 malignant melanoma cell lines have shown that they have a whitening effect on many types of dipeptides.
  • 32 showed more than 50% whitening efficacy, and 19 had 30-50% and 56 had 10-30% inhibitory effects.
  • All experiments using Mel-Ab cells showed more than 50% whitening efficacy in 34 species, 30-50% in 24 species, and 10-30% in 34 species.
  • the dipeptides showing the whitening effect were classified into more than 50% effect group (Group A above), 30-50% effect group (Group B above), and 10-30% effect group (Group C above). In the case of different cells, the two cells were classified as having good effects.
  • the whitening ability of the dipeptide produced by combining two amino acids was identified.
  • the first amino acid and the second amino acid are selected from tyrosine or tryptophan, and the third amino acid is tryptophan
  • Peptides with Korean Patent No. 10-2002-0016298 Melanin Production Inhibition Peptide, Method for Producing It, and External Skin Composition Containing the Same
  • the fourth amino acid has a whitening effect on a peptide consisting of a total of four amino acids consisting of arginine There is a difference in the number of.
  • the peptide is expected to increase in molecular weight along its length, increase the production price, and decrease the cell permeability.
  • the inventors have excellent whitening when using a peptide consisting of only two amino acids instead of a peptide consisting of four amino acids. Efficacy was confirmed, and even though it was not selected from tyrosine or tryptophan, it was confirmed that the peptide had various whitening effects.
  • Republic of Korea Patent 10-2002-0016298 searched for a peptide that inhibits the tyrosinase enzyme in vitro, the present inventors conducted a whitening ability identification experiment at the cellular level using melanin cell line.
  • Republic of Korea Patent 10-2002-0016298 shows a low whitening effect of 30-40% inhibition at the highest concentration of 1000uM, whereas the dipeptide of the present invention maximum at a low concentration of 30 ⁇ 50uM (peptide experiment concentration 10ug / ml) Almost 80% showed whitening efficacy. This result was presumed to be a phenomenon caused by the small peptide easily penetrated the cells.
  • Dipeptide libraries used in the following examples are Ala, Asn, Arg, Asp, Cys, Gln, Glu, Gly, His, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, A total of 400 dipeptide libraries prepared by linking 20 amino acids of Val 2 by 2 each, were purchased from the domestic manufacturer beadtech.
  • Phenolic red free treated with alpha-MSH 1uM was inoculated with 1x10 4 B16 malignant melanoma cell lines in 96 well plates for the melanin production inhibition test of B16 malignant melanoma cell line. Samples were added to DMEM medium at a concentration of 10 ug / ml and incubated for 3 days. After 3 days of incubation, the state of the cells was observed under a microscope and the amount of melanin was measured at an absorbance of 400 nm. Total cell number was calculated to correct the absorbance.
  • 1x10 5 Mel-Ab melanocytes were inoculated in 96-well plates for melanin production inhibition experiments on Mel-Ab melanocytes of dipeptides, and then cultured daily. Add and incubate for 4 days. Thereafter, the cells were dissolved in 1N NaOH, boiled at 100 ° C. for 30 minutes to completely lyse, and the melanin amount was measured at an absorbance of 400 nm.
  • C is the melanin concentration of the control sample (ug of melanin / ug of protein)
  • A is the sample melanin concentration (ug of melanin / ug of protein).
  • B16 malignant melanoma cell lines have shown that they have a whitening effect on many types of dipeptides. Of the total 400 species, 32 showed more than 50% of whitening efficacy, 19 of 30 ⁇ 50%, 56 of 10 ⁇ 30% of the inhibitory effect was shown (Table 1). Groups showing 10% or less efficacy were judged to be ineffective.
  • aqueous phase component and oil phase component were heated to 75 ° C. at the composition ratios of Formulation Example 1 and Formulation Example 2 shown in Table 3 below, and the oil phase component was mixed with the aqueous phase component. After adding a neutralizing agent to the mixture and cooling to 40 ° C., a creamy emulsion was prepared by adding a perfume and any one dipeptide selected from groups A to C.
  • 'Peptide' added in Table 3 is any one peptide selected from Groups A to C.
  • Ointment was prepared according to a conventional ointment preparation method with 6.0% (w / w), an amount of paraoxybenzoic acid ester and a residual amount of petrolatum.

Abstract

L'invention concerne une composition de blanchiment de la peau contenant un peptide constitué de deux acides aminés, ledit peptide améliorant significativement les effets de blanchiment de la peau par rapport à un peptide classique constitué de quatre acides aminés. La composition permet de réduire grandement les coûts par utilisation de petits peptides, et peut être utilisée comme composition de maquillage (cosmétique) ou comme produit médicinal pour la peau, tel qu'un onguent, ladite composition pouvant être utilisée seule ou en combinaison avec d'autres ingrédients ayant des capacités de blanchiment de la peau.
PCT/KR2010/002159 2010-04-08 2010-04-08 Composition de blanchiment de la peau contenant un dipeptide WO2011126163A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/002159 WO2011126163A1 (fr) 2010-04-08 2010-04-08 Composition de blanchiment de la peau contenant un dipeptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2010/002159 WO2011126163A1 (fr) 2010-04-08 2010-04-08 Composition de blanchiment de la peau contenant un dipeptide

Publications (1)

Publication Number Publication Date
WO2011126163A1 true WO2011126163A1 (fr) 2011-10-13

Family

ID=44763086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/002159 WO2011126163A1 (fr) 2010-04-08 2010-04-08 Composition de blanchiment de la peau contenant un dipeptide

Country Status (1)

Country Link
WO (1) WO2011126163A1 (fr)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103739666A (zh) * 2013-12-30 2014-04-23 浙江树人大学 具有降血压和降血脂双功能的二肽qe及其用途
CN103992373A (zh) * 2014-06-05 2014-08-20 浙江省农业科学院 具有降血糖功能的二肽if及其用途
US9655834B1 (en) * 2016-02-23 2017-05-23 Renorigin Innovation Institute Co., Ltd. Peptide, method and composition for inhibiting melanogenesis
WO2017116138A1 (fr) * 2015-12-28 2017-07-06 주식회사 젬백스앤카엘 Peptide inhibiteur de la mélanine et composition le contenant
WO2017162879A1 (fr) 2016-03-24 2017-09-28 Cysal Gmbh Aspartyl-dipeptides pour le soin de la peau et l'utilisation cosmétique
WO2017213456A3 (fr) * 2016-06-09 2018-01-25 주식회사 루비크라운 Peptide ayant une activité inhibant la mélanogénèse et composition le comprenant
JP2018177691A (ja) * 2017-04-13 2018-11-15 株式会社協和 メラニン生成抑制剤
US10729628B2 (en) 2015-12-24 2020-08-04 Conopco, Inc. Tyrosinase inhibitors
KR20200125239A (ko) * 2019-04-26 2020-11-04 계명대학교 산학협력단 갈색거저리 유충의 단백가수분해물로부터 분리된 펩타이드 및 이를 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
US11241474B2 (en) * 2013-12-27 2022-02-08 Colgate-Palmolive Company Prebiotic oral care compositions containing amino acids
CN114315958A (zh) * 2022-01-11 2022-04-12 北京志道生物科技有限公司 一种化合物及其应用
WO2022168939A1 (fr) * 2021-02-05 2022-08-11 国立大学法人九州大学 Agent favorisant l'expression génique de la céramide synthase, agent améliorant la peau, aliment fonctionnel pour amélioration de la peau, produit cosmétique et procédé d'utilisation de dipeptide
CN115386625A (zh) * 2022-08-18 2022-11-25 宁波赛缪斯生物科技有限公司 一种基于抗光、污基因定制护肤品的方法与护肤品

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05170636A (ja) * 1991-12-25 1993-07-09 Narisu Keshohin:Kk 美白化粧料
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
WO2007058612A1 (fr) * 2005-11-15 2007-05-24 Entress Ab Medicament a utiliser en rapport avec la deterioration de cartilage
US20080108684A1 (en) * 2005-07-01 2008-05-08 Ajinomoto Co., Inc. Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05170636A (ja) * 1991-12-25 1993-07-09 Narisu Keshohin:Kk 美白化粧料
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
US20080108684A1 (en) * 2005-07-01 2008-05-08 Ajinomoto Co., Inc. Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor
WO2007058612A1 (fr) * 2005-11-15 2007-05-24 Entress Ab Medicament a utiliser en rapport avec la deterioration de cartilage

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241474B2 (en) * 2013-12-27 2022-02-08 Colgate-Palmolive Company Prebiotic oral care compositions containing amino acids
CN103739666A (zh) * 2013-12-30 2014-04-23 浙江树人大学 具有降血压和降血脂双功能的二肽qe及其用途
CN103992373A (zh) * 2014-06-05 2014-08-20 浙江省农业科学院 具有降血糖功能的二肽if及其用途
US10729628B2 (en) 2015-12-24 2020-08-04 Conopco, Inc. Tyrosinase inhibitors
WO2017116138A1 (fr) * 2015-12-28 2017-07-06 주식회사 젬백스앤카엘 Peptide inhibiteur de la mélanine et composition le contenant
KR20180089440A (ko) 2015-12-28 2018-08-08 주식회사 젬백스앤카엘 멜라닌 억제 기능성 펩티드 및 이를 포함하는 조성물
CN107098951B (zh) * 2016-02-23 2020-08-04 肌活丽学创研所股份有限公司 降低黑色素含量的胜肽、方法及组合物
US9655834B1 (en) * 2016-02-23 2017-05-23 Renorigin Innovation Institute Co., Ltd. Peptide, method and composition for inhibiting melanogenesis
CN107098951A (zh) * 2016-02-23 2017-08-29 肌活丽学创研所股份有限公司 降低黑色素含量的胜肽、方法及组合物
US9814663B2 (en) 2016-02-23 2017-11-14 Renorigin Innovation Institute Co., Ltd. Peptide, method and composition for inhibiting melanogenesis
WO2017162879A1 (fr) 2016-03-24 2017-09-28 Cysal Gmbh Aspartyl-dipeptides pour le soin de la peau et l'utilisation cosmétique
US11020337B2 (en) 2016-03-24 2021-06-01 Cysal Gmbh Aspartyl-dipeptides for skin care and cosmetic use
WO2017213456A3 (fr) * 2016-06-09 2018-01-25 주식회사 루비크라운 Peptide ayant une activité inhibant la mélanogénèse et composition le comprenant
JP2018177691A (ja) * 2017-04-13 2018-11-15 株式会社協和 メラニン生成抑制剤
JP7132561B2 (ja) 2017-04-13 2022-09-07 株式会社協和 メラニン生成抑制剤
KR20200125239A (ko) * 2019-04-26 2020-11-04 계명대학교 산학협력단 갈색거저리 유충의 단백가수분해물로부터 분리된 펩타이드 및 이를 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
WO2020218727A3 (fr) * 2019-04-26 2020-12-30 계명대학교 산학협력단 Peptide isolé dans un hydrolysat de protéines du ver de farine tenebrio molitor et composition le comprenant en tant que principe actif pour prévenir ou traiter une atteinte hépatique
KR102252483B1 (ko) * 2019-04-26 2021-05-14 계명대학교 산학협력단 갈색거저리 유충의 단백가수분해물로부터 분리된 펩타이드 및 이를 유효성분으로 포함하는 간 손상 예방 또는 치료용 조성물
WO2022168939A1 (fr) * 2021-02-05 2022-08-11 国立大学法人九州大学 Agent favorisant l'expression génique de la céramide synthase, agent améliorant la peau, aliment fonctionnel pour amélioration de la peau, produit cosmétique et procédé d'utilisation de dipeptide
CN114315958A (zh) * 2022-01-11 2022-04-12 北京志道生物科技有限公司 一种化合物及其应用
CN114315958B (zh) * 2022-01-11 2023-07-25 北京志道生物科技有限公司 一种化合物及其应用
CN115386625A (zh) * 2022-08-18 2022-11-25 宁波赛缪斯生物科技有限公司 一种基于抗光、污基因定制护肤品的方法与护肤品

Similar Documents

Publication Publication Date Title
KR101222685B1 (ko) 다이펩타이드를 포함하는 피부 미백용 화장품 조성물
WO2011126163A1 (fr) Composition de blanchiment de la peau contenant un dipeptide
EP1879549B1 (fr) Compositions cosmetiques comprenant un dipeptide
KR20150057918A (ko) 피부 미백용 조성물
EP2164858B1 (fr) Peptide kghk, son utilisation dans des applications cosmétiques et cosméceutiques, et compositions le comprenant
JP2003238387A (ja) 目の下のたるみおよびくまを緩和するための皮膚外用剤組成物
US20080095732A1 (en) Personal care compositions
EP2473517B1 (fr) Peptide activateur de la transglutaminase et composition cosmetique ou pharmaceutique le contenant
KR101870898B1 (ko) 갈릭산이 결합된 펩타이드 유도체 및 그를 포함하는 항노화 피부 외용제 조성물
WO2018034453A1 (fr) Conjugué de minoxidil et d'un peptide
NZ534450A (en) Method of stimulation of melanin production and induction of skin tanning comprising administering alpha-MSH and exposing skin to UV irradiation
JP2004131401A (ja) 皮膚化粧料
WO2022204305A2 (fr) Peptides et procédés de réduction de la pigmentation de la peau
CN108129551A (zh) 具有皮肤美白效果的肽及其用途
KR101308977B1 (ko) 시스테인-메티오닌 포함 트리펩타이드를 포함하는 피부 미백용 화장품 조성물
WO2018151352A1 (fr) Conjugué d'acide salicylique et de peptide
KR101553032B1 (ko) 니아졸을 함유하는 피부 미백용 조성물
KR100497151B1 (ko) 신규한 펩타이드 화합물 및 그 용도
KR100505469B1 (ko) 신규한 펩타이드 화합물 및 그 용도
KR20160119548A (ko) 현삼 온수 추출물을 유효성분으로 함유하는 피부미백용 조성물
WO2018208124A2 (fr) Conjugué d'isotrétinoïne et d'un peptide
Choi et al. Whitening and Anti-inflammatory Effects of Geranium maculatum Liposomes
KR101151364B1 (ko) 페오니플로린을 포함하는 피부주름 개선제
AU2014271339A1 (en) Personal care compositions
KR102084521B1 (ko) 여드름 예방 및 개선용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10849510

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10849510

Country of ref document: EP

Kind code of ref document: A1